1994-09 to 1997-06 Ph.D.: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
1991-09 to 1994-06 Master's: Lanzhou University
2012 National Outstanding Youth Science Fund
2005-05 to Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Researcher
2001-08 to 2005-05 - Vivoquest Inc., USA - Senior Researcher in Medicinal Chemistry
2001-04 to 2001-07 - Rockefeller University, USA - Postdoctoral Researcher
2000-08 to 2001-04 - Harvard Medical School, USA - Postdoctoral Researcher
1998-09 to 2000-08 - Georgetown University Medical Center, USA - Postdoctoral Researcher
1997-09 to 1998-07 - Nagoya University, Japan - Postdoctoral Researcher
2016: Second Prize for Research on Key Technologies for the Preparation of Drug-like and Targeted Compound Libraries
2012: First Prize, National Outstanding Youth
2011: First Prize, Zhu Li Yuehua Excellent Teacher Award
2010: First Prize, Chinese Pharmaceutical Association Youth Biopharmaceutical Award
Research
Synthesis of Drug-like and Natural Product-like Scaffolds Discovery and Optimization of Novel Active Compounds Development of Candidate Drugs Design and Synthesis of Small Molecule Probes
Antiviral Research, Not mentioned, 2024
RSC Medicinal Chemistry, Not mentioned, 2024
JOURNAL OF MEDICINAL CHEMISTRY, Not mentioned, 2023
Research on Liver-Targeted Drugs Based on Asialoglycoprotein Receptor, Long Guozhang, Zhang Zhuo, Chen Wuhong, Hu Youhong, 2023
Discovery of (S)-N-(2-Amino-4-fluorophenyl)-4-(1-(3-(4-((dimethylamino)methyl)phenyl)-6-oxopyridazin-1(6H)-yl)ethyl)benzamide as Potent Class I Selective HDAC Inhibitor for Oral Anticancer Drug Candidate, Li Daqiang, Zhang Zhuo, Li Yalei, Wang Xinyi, Zhong Hanyue, Yang Huajie, Xi Yong, Liu Hongchun, Shen Aijun, Hu Youhong, 2023
A prodrug of the capsid assembly modulator improved druggability and lowing HBsAg and HBeAg for the treatment of chronic hepatitis B, Chen Wuhong, Gong Ying, Long Guozhang, Wang Xinran, Yang Yurong, Liu Jia, Li Heng, Tong Xiankun, Zhao Qiliang, Yang Li, Zuo Jianping, Hu Youhong, 2023
Discovery of selective NaV1.8 inhibitors based on 5-chloro-2-(4,4-difluor- oazepan-1-yl)-6-methyl nicotinamide scaffold for the treatment of pain, Qin Hui, Wei Aihuan, Wang Yunqi, Wang Linlin, Xu Haiyan, Zhan Yan, Tian Xuechen, Zheng Yueming, Gao Zhaobing, Hu Youhong, 2023
Discovery of novel heteroaryl alkynes for highly potent KITD816V cells inhibition to treat gastrointestinal stromal tumors, Xie Zhicheng, Li Lin, Guo Yihao, Zhang Mi, Chen Taiwen, Li Yongpeng, Li Xin, Zhu Xi, Zhang Yu, Lou Liguan, Hu Youhong, 2022
Protein C-Terminal Tyrosine Conjugation via Recyclable Immobilized BmTYR, Ji Xingyu, Zhu Nanlin, Ma Yanjie, Liu Jia, Hu Youhong, 2022
Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold, Sheng Han, Heng Li, Weixiong Chen, Li Yang, Xiankun Tong, Jianping Zuo, Youhong Hu, 2022
Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold, Chen Jingjing, He Huixin, Wei Aihuan, Li Yalei, Cheng Gang, Qin Hui, Zhong Hanyue, Liu Hongchun, Geng Meiyu, Shen Aijun, Hu Youhong, 2022
Discovery of highly potent SARS-CoV-2 M-pro inhibitors based on benzoisothiazolone scaffold, Chen Weixiong, Feng Bo, Han Sheng, Wang Peipei, Chen Wuhong, Zang Yi, Li Jia, Hu Youhong, 2022
A novel low systemic diacylglycerol acyltransferase 1 inhibitor, Yhhu2407, improves lipid metabolism, Huang JunShang, Guo BinBin, Lin FeiFei, Zeng LiMin, Wang Ting, Dang XiangYu, Yang Yang, Hu YouHong, Liu Jia, Wang HeYao, 2021
GPR52 Antagonist Reduces Huntingtin Levels and Ameliorates Huntington's Disease-Related Phenotypes, Wang Congcong, Zhang YuFang, Guo Shimeng, Zhao Quan, Zeng Yanping, Xie Zhicheng, Xie Xin, Lu Boxun, Hu Youhong, 2021
Discovery of Potent Antiallergic Agents Based on an o-Aminopyridinyl Alkynyl Scaffold, Xie Zhicheng, Xiang Caigui, Li Xin, Fan Chen, Chen Taiwen, Liu Moting, Ma Yanjie, Bai Fang, Tang Wei, Hu Youhong, 2021
Discovery of 1,5-Dihydro-4H-imidazol-4-one Derivatives as Potent, Selective Antagonists of CXC Chemokine Receptor 2, Che Jinxin, Wang Zhilong, Shen Zheyuan, Zhuang Weihao, Ying Huazhou, Hu Yongzhou, Hu Youhong, Xie Xin, Dong Xiaowu, 2021
Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes, Chen Jingjing, Li Yalei, Zhang Jie, Zhang Minmin, Wei Aihuan, Liu Hongchun, Xie Zhicheng, Ren Wenming, Duan Wenwen, Zhang Zhuo, Shen Aijun, Hu Youhong, 2021
Novel Class of Colony-Stimulating Factor 1 Receptor Kinase Inhibitors Based on an o-Aminopyridyl Alkynyl Scaffold as Potential Treatment for Inflammatory Disorders, Xie Zhicheng, Wu Bing, Liu Yingqiang, Ren Wenming, Tong Linjiang, Xiang Caigui, Wei Aihuan, Gao Yuanzhuo, Zeng Limin, Xie Hua, Tang Wei, Hu Youhong, 2020
Targeted Proteomics Combined with Affinity Mass Spectrometry Analysis Reveals Antagonist E7 Acts As an Intracellular Covalent Ligand of Orphan Receptor GPR52, Ma Mengna, Guo Shimeng, Lin Xi, Li Shanshan, Wu Yiran, Zeng Yanping, Hu Youhong, Zhao Suwen, Xu Fei, Xie Xin, Shui Wenqing, 2020
DGAT1 inhibitors protect pancreatic beta-cells from palmitic acid-induced apoptosis, Huang Junshang, Guo Binbin, Wang Gaihong, Zeng Limin, Hu Youhong, Wang Ting, Wang Heyao, 2020
Discovery of Phthalazinone Derivatives as Novel Hepatitis B Virus Capsid Inhibitors, Chen Wuhong, Liu Feifei, Zhao Qiliang, Ma Xinna, Lu Dong, Li Heng, Zeng Yanping, Tong Xiankun, Zeng Limin, Liu Jia, Yang Li, Zuo Jianping, Hu Youhong, 2020
NaH Promoted One-Pot Tandem Reactions of 3-(1-Alkynyl) Chromones to Form 2-Nitrogen-Substituted Xanthones, WenDi Duan, YuFang Zhang, Youhong Hu, 2020
Visualizing Autophagic Flux during Endothelial Injury with a Pathway-Inspired Tandem-Reaction Based Fluorogenic Probe, Lei Yu, Ren Wenming, Wang ChengKun, Tao RongRong, Xiang HuaiJiang, Feng LiLi, Gao YinPing, Jiang Quan, Li Xin, Hu Youhong, Han Feng, 2019
Base-Promoted Cascade Reactions of 3-(1-Alkynyl)chromones with Pyridinium Ylides to Chromeno2,3-dazepine Derivatives, Zhang YuFang, Duan WenDi, Chen Jingjing, Hu Youhong, 2019
The discovery of novel small molecular CXCR2 antagonist by using ligand-based pharmacophore model, Huang WenHai, Wang ZhiLong, Che JinXin, Sheng HaiChao, Huang Feng, Hu YongZhou, Hu YouHong, Xie Xin, Dong XiaoWu, 2018
Bicyclo2.2.1heptane containing N,N-diarylsquaramide CXCR2 selective antagonists as anti-cancer metastasis agents, Che JinXin, Wang ZhiLong, Dong XiaoWu, Hu YouHong, Xie Xin, Hu YongZhou, 2018
Fluorescent Imaging of beta-Amyloid Using BODIPY Based Near-Infrared Off-On Fluorescent Probe, Ren Wenming, Zhang Jingjing, Peng Cheng, Xiang Huaijiang, Chen Jingjing, Peng Chengyuan, Zhu Weiliang, Huang Ruimin, Zhang Haiyan, Hu Youhong, 2018
Targeting Gpr52 lowers mutant HTT levels and rescues Huntington's disease-associated phenotypes, Song Haikun, Li Hexuan, Guo Shimeng, Pan Yuyin, Fu Yuhua, Zhou Zijian, Li Zhaoyang, Wen Xue, Sun Xiaoli, He Bingqing, Gu Haifeng, Zhao
Area of Focus
Natural Products | Active Compounds | Unique Structures | Pharmacological Basis | Traditional Chinese Medicine | Lead Compounds | Structural Modification | Optimization | Discovery | Research
